MICHAEL O. THORNER, M.B.; WILLIAM S. EVANS, M.D.; G. M. BESSER, M.D.; WASS J. A. H., M.B.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Drs. Spark and Dickstein have presented an excellent overview of the role of bromocriptine in the treatment of endocrine disorders (1). We wish, however, to comment on several points.
The authors correctly emphasize that in hyperprolactinemic men the clinical presentation is usually that of symptoms secondary to tumor expansion, such as visual-field defects, whereas in women, menstrual disorders or galactorrhea, or both, are the predominant presenting features. However, they also emphasize that these men are infertile due to oligospermia or impotence. Although we agree that impotence and low serum testosterone levels prevail in these men, in our
THORNER MO, EVANS WS, BESSER GM, et al. Bromocriptine and Endocrine Disorders. Ann Intern Med. 1979;91:652. doi: 10.7326/0003-4819-91-4-652_1
Download citation file:
Published: Ann Intern Med. 1979;91(4):652.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use